These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19680259)

  • 1. Prevention of local lipotoxicity: a new renoprotective mechanism of peroxisome proliferator-activated receptor-alpha activation in hypertension and obesity?
    Zhao X
    Hypertens Res; 2009 Oct; 32(10):821-3. PubMed ID: 19680259
    [No Abstract]   [Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats.
    Shin SJ; Lim JH; Chung S; Youn DY; Chung HW; Kim HW; Lee JH; Chang YS; Park CW
    Hypertens Res; 2009 Oct; 32(10):835-45. PubMed ID: 19644507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nuclear receptors PPARalpha].
    Soska V
    Vnitr Lek; 2006 Jun; 52(6):628-31. PubMed ID: 16871768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
    Fruchart JC; Duriez P
    Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleiotropic effects of fibrates.
    Chinetti-Gbaguidi G; Fruchart JC; Staels B
    Curr Atheroscler Rep; 2005 Sep; 7(5):396-401. PubMed ID: 16105484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrates in CVD: a step towards personalised medicine.
    Staels B
    Lancet; 2010 May; 375(9729):1847-8. PubMed ID: 20510999
    [No Abstract]   [Full Text] [Related]  

  • 7. Factors modulating fibrates response: therapeutic implications and alternative strategies.
    Panadero MI; González MC; Herrera E; Bocos C
    Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):219-36. PubMed ID: 19594420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrates, glitazones, and peroxisome proliferator-activated receptors.
    Lalloyer F; Staels B
    Arterioscler Thromb Vasc Biol; 2010 May; 30(5):894-9. PubMed ID: 20393155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice.
    Takei K; Han SI; Murayama Y; Satoh A; Oikawa F; Ohno H; Osaki Y; Matsuzaka T; Sekiya M; Iwasaki H; Yatoh S; Yahagi N; Suzuki H; Yamada N; Nakagawa Y; Shimano H
    J Diabetes Investig; 2017 Jul; 8(4):446-452. PubMed ID: 28084058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 2-heteroarylthioalkanoic acid analogues of clofibric acid as peroxisome proliferator-activated receptor alpha agonists.
    Giampietro L; Ammazzalorso A; Giancristofaro A; Lannutti F; Bettoni G; De Filippis B; Fantacuzzi M; Maccallini C; Petruzzelli M; Morgano A; Moschetta A; Amoroso R
    J Med Chem; 2009 Oct; 52(20):6224-32. PubMed ID: 19791744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lipid-lowering pharmaceuticals bezafibrate and clofibric acid on lipid metabolism in fathead minnow (Pimephales promelas).
    Weston A; Caminada D; Galicia H; Fent K
    Environ Toxicol Chem; 2009 Dec; 28(12):2648-55. PubMed ID: 19522550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular pharmacology and medicinal chemistry of fibrate].
    Steinhilber D; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2007; 36(2):108-12. PubMed ID: 17424995
    [No Abstract]   [Full Text] [Related]  

  • 13. The potential use of PPARalpha agonists as immunosuppressive agents.
    Cunard R
    Curr Opin Investig Drugs; 2005 May; 6(5):467-72. PubMed ID: 15912959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α pathway.
    Chung HW; Lim JH; Kim MY; Shin SJ; Chung S; Choi BS; Kim HW; Kim YS; Park CW; Chang YS
    Nephrol Dial Transplant; 2012 Jun; 27(6):2213-25. PubMed ID: 22076434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy.
    Varghese Z; Moorhead JF; Ruan XZ
    Kidney Int; 2006 May; 69(9):1490-1. PubMed ID: 16672917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the PPAR-α agonist fenofibrate in severe pediatric burn.
    Elijah IE; Børsheim E; Maybauer DM; Finnerty CC; Herndon DN; Maybauer MO
    Burns; 2012 Jun; 38(4):481-6. PubMed ID: 22226866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mulberry extract inhibits oleic acid-induced lipid accumulation via reduction of lipogenesis and promotion of hepatic lipid clearance.
    Ou TT; Hsu MJ; Chan KC; Huang CN; Ho HH; Wang CJ
    J Sci Food Agric; 2011 Dec; 91(15):2740-8. PubMed ID: 22002411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating effects of chlorogenic acid on lipids and glucose metabolism and expression of hepatic peroxisome proliferator-activated receptor-alpha in golden hamsters fed on high fat diet.
    Li SY; Chang CQ; Ma FY; Yu CL
    Biomed Environ Sci; 2009 Apr; 22(2):122-9. PubMed ID: 19618689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease.
    Guan Y
    Minerva Urol Nefrol; 2002 Jun; 54(2):65-79. PubMed ID: 12185990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of PPAR-alpha agonists in the prevention of CVD in diabetes.
    Taskinen MR
    Curr Diab Rep; 2007 Apr; 7(2):83-5. PubMed ID: 17425910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.